FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1586594128> ?p ?o ?g. }

• W1586594128 endingPage "1242" @default.
• W1586594128 startingPage "1228" @default.
• W1586594128 abstract "What's known on the subject? and What does the study add? Novel therapeutic methods have emerged in recent years as ‘focal’ treatment alternatives in which cancer foci can be eradicated and greatly reducing the associated side-effects of radical treatment. High-intensity focused ultrasound (HIFU) seems to result in a well fitted technology, which has proven short- to medium-term cancer control, with a low rate of complications comparable with those of established therapies. This is an up-to-date review of the available literature on HIFU as a definitive treatment of prostate cancer. It describes the technique in a comprehensive approach in terms of technical features, procedure, indications, and gives an overview of its historical background; finally, we present the future applications of HIFU and its development trend. OBJECTIVES • To provide an up-to-date review of the available literature on high-intensity focused ultrasound (HIFU) as a definitive treatment of prostate cancer. • To present the technique in a comprehensive approach, comparing the available devices according to the existing evidence in terms of technical features, procedure, indications, and to give an overview of its historical background; and finally, to discuss future applications of HIFU and its development trend. MATERIALS AND METHODS • A systematic literature search was conducted using MEDLINE and EMBASE via Ovid databases (January 2000 to December 2011), to identify studies on HIFU for treatment of prostate cancer. • Only English-language and human-based full manuscripts that reported on case series studies with >50 participants, patient characteristics, efficacy and safety data were included. RESULTS • No randomised controlled trials were identified by the literature search. We identified 31 uncontrolled studies that examined the efficacy of HIFU as primary treatment and two studies that examined the efficacy of HIFU as salvage treatment. • Most treated patients had localised prostate cancer (stage T1–T2); Gleason scores of 2–10 and mean prostate specific antigen (PSA) values of 4.6–12.7 ng/mL. The mean age range of the patients was 64.1–72 years. The mean follow-up ranged from 6.4 to 76.8 months. Negative biopsy rates ranged from 35 to 95%. PSA nadirs ranged from 0.04 to 1.8 ng/mL. The 5-year disease-free survival rates ranged from 61.2 to 95%; 7- and 8-year disease free survival rates ranged from 69 to 84%. • The most common complications associated with the HIFU procedure as the primary treatment included: urinary retention (<1–20%); urinary tract infections (1.8–47.9%); stress or urinary incontinence (<1–34.3%); and erectile dysfunction (20–81.6%). • Recto-urethral fistula was reported in <2% of patients. • Treatment-related morbidity appeared to be reduced by the combination of transurethral resection (TURP) of the prostate and HIFU. CONCLUSIONS • Novel therapeutic methods have emerged in recent years as ‘focal’ treatment alternatives, in which cancer foci could be eradicated by greatly reducing the associated side-effects of radical treatment. • HIFU seems to result in short- to medium-term cancer control, with a low rate of complications comparable with those of established therapies. • However, longer-term follow-up studies are needed to evaluate cancer-specific and overall survival. If available promising results on HIFU for definitive treatment of prostate cancer are confirmed in future prospective trials, focal therapy could start to challenge the current standard of care." @default.
• W1586594128 created "2016-06-24" @default.
• W1586594128 creator A5016184390 @default.
• W1586594128 creator A5040514321 @default.
• W1586594128 creator A5066220603 @default.
• W1586594128 creator A5080354002 @default.
• W1586594128 creator A5082495905 @default.
• W1586594128 creator A5090946201 @default.
• W1586594128 date "2012-06-06" @default.
• W1586594128 modified "2023-10-17" @default.
• W1586594128 title "High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer" @default.
• W1586594128 cites W1505962820 @default.
• W1586594128 cites W1558392243 @default.
• W1586594128 cites W1562028792 @default.
• W1586594128 cites W1567472737 @default.
• W1586594128 cites W1915803833 @default.
• W1586594128 cites W1965717154 @default.
• W1586594128 cites W1967197865 @default.
• W1586594128 cites W1967531287 @default.
• W1586594128 cites W1967832754 @default.
• W1586594128 cites W1970014288 @default.
• W1586594128 cites W1970203359 @default.
• W1586594128 cites W1970691211 @default.
• W1586594128 cites W1971886854 @default.
• W1586594128 cites W1982311990 @default.
• W1586594128 cites W1982386852 @default.
• W1586594128 cites W1983145936 @default.
• W1586594128 cites W1984222175 @default.
• W1586594128 cites W1985752624 @default.
• W1586594128 cites W1985962834 @default.
• W1586594128 cites W1986134680 @default.
• W1586594128 cites W1994258030 @default.
• W1586594128 cites W1994515728 @default.
• W1586594128 cites W1995055592 @default.
• W1586594128 cites W1995067043 @default.
• W1586594128 cites W1996741497 @default.
• W1586594128 cites W1997394967 @default.
• W1586594128 cites W1999913431 @default.
• W1586594128 cites W2005184420 @default.
• W1586594128 cites W2011874271 @default.
• W1586594128 cites W2013183573 @default.
• W1586594128 cites W2013332883 @default.
• W1586594128 cites W2014966452 @default.
• W1586594128 cites W2020762361 @default.
• W1586594128 cites W2021393151 @default.
• W1586594128 cites W2023139341 @default.
• W1586594128 cites W2023798810 @default.
• W1586594128 cites W2026459096 @default.
• W1586594128 cites W2028609618 @default.
• W1586594128 cites W2034725282 @default.
• W1586594128 cites W2040538815 @default.
• W1586594128 cites W2043275267 @default.
• W1586594128 cites W2048304411 @default.
• W1586594128 cites W2048944905 @default.
• W1586594128 cites W2051035889 @default.
• W1586594128 cites W2053179102 @default.
• W1586594128 cites W2057510074 @default.
• W1586594128 cites W2058126130 @default.
• W1586594128 cites W2058730737 @default.
• W1586594128 cites W2059688994 @default.
• W1586594128 cites W2060974422 @default.
• W1586594128 cites W2063456541 @default.
• W1586594128 cites W2066705460 @default.
• W1586594128 cites W2069948953 @default.
• W1586594128 cites W2072058446 @default.
• W1586594128 cites W2073833346 @default.
• W1586594128 cites W2074359793 @default.
• W1586594128 cites W2084713534 @default.
• W1586594128 cites W2085664899 @default.
• W1586594128 cites W2085889654 @default.
• W1586594128 cites W2087142672 @default.
• W1586594128 cites W2087981209 @default.
• W1586594128 cites W2094043660 @default.
• W1586594128 cites W2096413175 @default.
• W1586594128 cites W2097591339 @default.
• W1586594128 cites W2100342702 @default.
• W1586594128 cites W2102911743 @default.
• W1586594128 cites W2104377141 @default.
• W1586594128 cites W2104737923 @default.
• W1586594128 cites W2105454326 @default.
• W1586594128 cites W2106787323 @default.
• W1586594128 cites W2117792530 @default.
• W1586594128 cites W2118713781 @default.
• W1586594128 cites W2122321179 @default.
• W1586594128 cites W2127423431 @default.
• W1586594128 cites W2129806101 @default.
• W1586594128 cites W2134894853 @default.
• W1586594128 cites W2135369558 @default.
• W1586594128 cites W2138099766 @default.
• W1586594128 cites W2138310647 @default.
• W1586594128 cites W2139549698 @default.
• W1586594128 cites W2140402608 @default.
• W1586594128 cites W2146699704 @default.
• W1586594128 cites W2147799242 @default.
• W1586594128 cites W2151435813 @default.
• W1586594128 cites W2154870334 @default.
• W1586594128 cites W2156549595 @default.
• W1586594128 cites W2156677943 @default.

• next